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ABSTRACT: Glioblastoma multiforme (GBM) is the most aggressive
malignant primary brain tumor, with a dismal mean survival even with the
current standard of care. Although in vitro cell systems can provide
mechanistic insight into the regulatory networks governing GBM cell
proliferation and migration, clinical samples provide a more physiologically
relevant view of oncogenic signaling networks. However, clinical samples are
not widely available and may be embedded for histopathologic analysis. With
the goal of accurately identifying activated signaling networks in GBM tumor
samples, we investigated the impact of embedding in optimal cutting
temperature (OCT) compound followed by ﬂash freezing in LN2 vs
immediate ﬂash freezing (iFF) in LN2 on protein expression and
phosphorylation-mediated signaling networks. Quantitative proteomic and
phosphoproteomic analysis of 8 pairs of tumor specimens revealed minimal
impact of the diﬀerent sample processing strategies and highlighted the large
interpatient heterogeneity present in these tumors. Correlation analyses of the diﬀerentially processed tumor sections identiﬁed
activated signaling networks present in selected tumors and revealed the diﬀerential expression of transcription, translation, and
degradation associated proteins. This study demonstrates the capability of quantitative mass spectrometry for identiﬁcation of in
vivo oncogenic signaling networks from human tumor specimens that were either OCT-embedded or immediately ﬂash-frozen.
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■ INTRODUCTION
Glioblastoma multiforme (GBM) accounts for 12−15% of all
intracranial tumors and 50−60% of all astrocytic tumors,
making it the most common primary brain tumor. The current
standard of care for GBM consists of surgical removal,
radiotherapy, and chemotherapy treatment with the alkylating
agent Temozolomide.1,2 Despite these interventions the
median survival times remain at 9−14 months following
diagnosis.3 Over the past decade, genetic and transcriptional
characterization of GBMs has led to the identiﬁcation of
multiple genetic aberrations across a diverse array of genes.4
Speciﬁcally, the overexpression of RTKs in >80% of all GBMs
indicates a signiﬁcant involvement of RTKs in the tumor
remodelling of cells in GBM.4 The epidermal growth factor
receptor (EGFR), platelet-derived growth factor receptor alpha
(PDGFRα),5,6 platelet-derived growth factor receptor beta
(PDGFRβ),5 and the hepatocyte growth factor receptor (Met/
HGFR)7 have each been shown to play critical roles in GBM
pathology and resistance to RTK targeted therapeutics. The
combination of genotyping and gene expression proﬁling has
led to the identiﬁcation of four subclasses of GBM tumors
classical, mesenchymal, neural, and proneural, with each
subtype driven by mutation/deregulated expression of EGFR,
NF1, FBXO3, and PDGFRα/IDH1 respectively.6,8,9 Thus, the
signiﬁcant alteration of RTKs across human GBMs indicates a
need for an increased understanding of activated phosphotyr-
osine signaling pathways at the molecular level.
Stratiﬁcation of patients based on molecular tumor character-
istics to enable more eﬀective treatment strategies (i.e.,
personalized medicine) relies on the identiﬁcation of molecular
markers indicative of survival.10,11 Identiﬁcation of regulatory
signaling networks in GBM would be of signiﬁcant importance
for stratifying patients in clinical trials. It has recently become
possible to quantify phosphorylation events across patient
samples with high sensitivity and throughput. For instance,
panels of antibodies to phosphorylation sites can be used to
probe tumor lysates on reverse phase protein arrays.12,13
Furthermore, immunoprecipitation of phosphotyrosine pep-
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tides followed by mass spectrometric analysis has been used to
identify activated signaling pathways within clinical lung
carcinoma and prostate tumors.14,15 Additionally, we have
previously quantiﬁed phosphotyrosine signaling diﬀerences
across a panel of eight human GBM patient derived xenograft
(PDX) tumors with diﬀering expression of EGFRvIII.16
Identiﬁcation and quantiﬁcation of phosphotyrosine signaling
and protein expression proﬁles emphasized the signiﬁcant
heterogeneity of the disease across the eight PDX tumors and
allowed the identiﬁcation of proteins that were correlated with
poor survival in EGFRvIII driven GBM.16
Although the identiﬁcation of signaling in in vivo systems is
critically important to understand the eﬀects of altered RTK
activation in glioblastoma, diﬀerences in extracellular growth
environments have a signiﬁcant impact on molecular proﬁles of
cells, as tumor cells grown intracranially, subcutaneously and on
tissue culture plastic were have been shown to induce the
expression of distinct sets of genes.17 Accurate identiﬁcation of
physiological tumor signaling therefore necessitates a move
toward quantitative analysis of protein phosphorylation in
clinical samples. The limited availability of clinical samples for
proteomic analysis remains an issue that is further compounded
by the diﬀerential processing of tumor samples prior to
pathological analysis and long-term storage. Embedding tissues
for frozen sectioning is an important practice in histopathologic
analysis and as such formalin-ﬁxed paraﬃn embedded (FFPE)
and optimal cutting temperature (OCT) compound embed-
ding is routine in pathology laboratories.18 To exploit
diﬀerentially preserved tumor material it is paramount to
evaluate the ability to quantify activated signaling networks and
protein expression proﬁles across these tumors.19,20
With limited availability of clinical samples it is important to
utilize human GBM tumor sections that have been prepared
and stored in diﬀerent ways. To investigate the eﬀect of these
alternate storage methods on protein stability or protein post-
translational modiﬁcations, we have quantiﬁed activated
phosphotyrosine networks and proﬁled global protein
expression across eight pairs of human GBM tumor sections
that have been either embedded in OCT compound followed
by ﬂash freezing in LN2 or immediately ﬂash frozen in LN2.
Samples were labeled with isobaric tags and subsequent
enrichment of phosphotyrosine peptides was carried out.
Once phosphotyrosine proﬁling was completed, peptides
were fractionated and protein expression proﬁling was carried
out across the panel of human GBM tumors.16 Quantitative
proteomic analysis of these clinical samples has allowed us to
identify eﬀects of sample storage on the signaling and protein
expression proﬁles and enabled the identiﬁcation of oncogenic
signaling processes. Correlation analysis and functional analysis
of the quantitative proteomic data indicate groups of related
proteins that are coexpressed in GBM tumors and led to the
identiﬁcation of activated phosphotyrosine networks related to
GBM biology in vivo. Ultimately, these data demonstrate the
utility of quantitative phosphotyrosine analyses to identify the
activation of kinases and downstream signaling pathways in
vivo in the context of the inter- and intratumoral heterogeneity
present in GBM.
■ MATERIALS AND METHODS
Tissue Homogenization
Tumors were sourced from the brain tumor tissue bank of
Canada (www.Braintumourbank.com). The GBM tumors
included in this study have not been genetically subtyped.
Tumors were resected and immediately ﬂash frozen in LN2 or
embedded in OCT compound and ﬂash frozen in LN2 within 5
min (Table 1). OCT compound embedded tumors were rinsed
in ice cold PBS to remove the OCT compound around the
tissue prior to homogenization. Tumor sections were
homogenized (Polytron) in ice-cold 8 M urea for mass
spectrometric analyses or modiﬁed ice-cold radioimmunopre-
cipitation assay (RIPA) buﬀer for immunoblotting. Lysis buﬀers
were supplemented with 1 mM sodium orthovanadate, 0.1%
NP-40, and protease and phosphatase inhibitor cocktail tablets
(Roche). Samples were homogenized on ice. Protein
concentrations were quantiﬁed using a bicinchoninic acid
(BCA) assay (Pierce), and the total homogenate was stored at
−80 °C.
Immunoblotting
Cell lysates were separated on a 7.5% polyacrylamide gel and
electrophoretically transferred to nitrocellulose (Biorad). Nitro-
cellulose was blocked with 5% BSA in TBS-T (150 mM NaCl,
0.1% Tween 20, 50 mM Tris, pH 8.0). Antibodies used are as
follows: antiphosphotyrosine (4G10, Millipore), anti-EGFR
(BD Biosciences), anti-Her3/ErbB3 (CST), anti-PDGFRα
(CST), anti-PDGFRβ (CST), anti-Met (CST), anti-AKT
(CST), anti-AKT pS473 (CST), anti-p53 (CST), and anti-β-
tubulin (CST). Antibodies were diluted in blocking buﬀer and
incubated with nitrocellulose overnight at 4 °C. Secondary
antibodies (either goat antirabbit or goat antimouse conjugated
to horseradish peroxidase) were diluted 1:10 000 in TBS-T and
incubated at room temperature for 1 h. Antibody binding was
detected using the enhanced chemiluminescence (ECL)
detection kit (Pierce).
Mass Spectrometry Sample Preparation
Proteins were reduced (10 mM DTT, 56 °C for 45 min),
alkylated (50 mM iodoacetamide, room temperature in the
dark for 1 h), and excess iodoacetamide was quenched with
DTT to a ﬁnal concentration of 25 mM. Proteins were
subsequently digested with trypsin (sequencing grade, Prom-
Table 1. Tumor Sample Information: Sample ID, Diagnosis GBM (Grade IV), Patient Age at Tumor Resection, Patient Gender,
the Recurrence Status of the Tumor, Brain Region and Availability of OCT and iFF Tumor Sections
tumor # sample ID diagnosis age gender recurrent GBM? brain region OCT FF
1 2539 GBM 55 M yes right temporal x x
2 2568 GBM 40 M no right temporal xx
3 2556 GBM 47 F yes right parietal x x
4 2585 GBM 76 M yes left parietal x x
5 1789 GBM 75 F no / x x
6 2332 GBM 43 F yes right posterior thalamus x x
7 2442 GBM 70 M yes right frontal x x
8 2589 GBM 62 M no right frontal x x
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ega), at an enzyme/substrate ratio of 1:100, at room
temperature overnight in 100 mM ammonium acetate, pH
8.9. Trypsin activity was quenched by adding formic acid to a
ﬁnal concentration of 5%. Urea was removed from the samples
by reverse phase desalting using a C18 cartridge (Waters) and
peptides were lyophilized and stored at −80 °C.
iTRAQ Labeling
Peptide labeling with iTRAQ 8plex (AB Sciex) was performed
as previously described.16 For each analysis, ∼8 mg (wet
weight) of tumor (equivalent to 800 μg of peptide before
desalting and processing) for each of the tumors was labeled
with two tubes of iTRAQ 8plex reagent.
Phosphotyrosine Enrichment
Phosphotyrosine peptides were enriched prior to mass
spectrometry analyses using a cocktail of antiphosphotyrosine
antibodies followed by immobilized metal aﬃnity chromatog-
raphy (IMAC) as previously described.16,21
Peptide Isoelectric Focusing and Protein Expression
Proﬁling
iTRAQ labeled peptides were separated into ﬁve fractions using
the ZOOM isoelectric focusing (IEF) fractionator (Invitrogen)
with a set of six ZOOM disks (pH 3.0, pH 4.6, pH 5.4, pH 6.2,
pH 7.0, and pH 10) as previously described.14 Each fraction
was separated by reverse phase HPLC (Agilent) over a 240 min
gradient before nanoelectrospray into a 5600 triple time-of-
ﬂight (ToF) instrument (AB Sciex) operated in positive ion
mode.
Protein Expression Data Analysis
Relative quantiﬁcation and protein identiﬁcation were
performed with the ProteinPilot software (version 2.0; AB
Sciex) using the Paragon algorithm as the search engine. MS/
MS spectra were searched against human protein sequence
database (NCBInr, released May 2011, downloaded from ftp://
ftp.ncbi.nih.gov/genomes/H_sapiens/protein/). The search
parameters allowed for carbamidomethylation of cysteines by
iodoacetamide and a standard extensive list of biological
modiﬁcations that were programmed in the algorithm.
Identiﬁed proteins were grouped by the ProGroup algorithm
(AB Sciex) to minimize redundancy. The false discovery rate
(FDR) was calculated by searching the spectra against the
NCBI nonredundant Homo sapiens decoy database. Before
ﬁltering the protein expression data (explained above), the
protein level FDR was calculated at 1%, corresponding to 2054,
2304, 2009, and 1842 proteins in analyses 1a, 1b, 2a, and 2b,
respectively. After application of the above ﬁlter criteria, the
estimated FDR value was <1% (at the protein level) for each of
the biological replicates analyzed, indicating a high reliability in
the proteins identiﬁed. Peptide summaries were exported from
ProteinPilot and isotope correction and relative quantiﬁcation
was calculated in Excel. The total list of phosphotyrosine
peptides and proteins identiﬁed and quantiﬁed can be found in
Supporting Information Tables S1 and S2 respectively.
Figure 1. Quantiﬁcation of tyrosine phosphorylation signaling and protein expression proﬁles across eight OCT compound embedded and eight
ﬂash frozen GBM human tumors.(A) Experimental mass spectrometric workﬂow. Human GBM tumors and their processing status either OCT
compound embedded (O) or ﬂash frozen (F), are indicated at the top of panel. There were two available sections of ﬂash frozen tumor tissue from
patient 2, indicated by Fa and Fb. The * above 5 indicates that tumor tissue 5F was used to normalize the quantitative data across all analyses.
Sixteen diﬀerentially processed human GBM tumor sections were homogenized, reduced, alkylated, and digested with trypsin, and then peptides
were labeled with 8plex- iTRAQ. Phosphotyrosine peptide enrichment was carried out by IP using antiphosphotyrosine antibodies and analyzed by
LC−MS/MS. For protein expression proﬁling, peptides were fractionated by IEF based on their isoelectric point (pI). (B) Total phosphotyrosine
levels (pY) were identiﬁed across 16 human GBM tumor sections by immunoblotting. Expression levels of EGFR, Her3, PDGFRα, PDGFRβ, Met,
Akt, and p53 were identiﬁed across the panel of tumors. β-Tubulin was used as a loading control.
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Figure 2. Phosphotyrosine signaling is distinctly diﬀerent across diﬀerent GBM patients but similar between OCT and ﬂash frozen processed
tumors. (A) The 107 overlapping phosphotyrosine sites quantiﬁed across at least 14 OCT compound embedded and ﬂash frozen GBM tumor
sections are visualized in the heat map. iTRAQ ratios were normalized to tumor section 5F, normalized to the mean, and log2 transformed. Tumor
sections and tyrosine phosphorylation sites were hierarchically clustered using one minus Pearson’s correlation distance metric. Missing values in
tumors 2Fa, 2Fb, 3O, and 3F are shaded gray. (B) A correlation matrix of all 16 tumors sections based on the quantitative phosphotyrosine data. The
Pearson’s coeﬃcients between every pair of tumor sections are displayed in each box. The color bar indicates the correlation coeﬃcients, where red
indicates positive correlation and blue indicates negative correlation. (C) Log2-transformed iTRAQ intensities from the OCT (O) compound
embedded tumor sections (y axis) were plotted against the corresponding ﬂash frozen (F) tumor sections (x axis). A simple linear regression line was
drawn through the data points and the R2 values were determined for all eight GBM tumor pairs.
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Functional Data Analysis
All mass spectra corresponding to phosphotyrosine peptides
were manually validated using a previously described computer
aided manual validation (CAMV) software tool.22 Curated,
annotated spectra of the 402 identiﬁed and quantiﬁed
phosphotyrosine peptides can be found in Supporting
Information Figure S1. Unsupervised hierarchical clustering of
the mean normalized and log2-transformed phosphotyrosine
and protein expression quantitative iTRAQ data was generated
using GENE-E (http://www.broadinstitute.org/cancer/
software/GENE-E/index.html). One minus Pearson’s correla-
tion was used as a distance metric in all clustering analyses.
Pearson’s correlation analysis of the quantitative phosphotyr-
osine or protein expression proﬁles of the tumors was carried
out using Excel. P values were calculated using t approximation.
All heat maps were generated using GENE-E. Gene ontology
(GO) annotations were identiﬁed by uploading gene lists to the
Protein Analysis Through Evolutionary Relationships (PAN-
THER) classiﬁcation system (http://www.pantherdb.org/).
Interaction maps were generated using the Search Tool for
the Retrieval of Interacting Genes/Proteins (STRING)
program version 9.0 5 (http://string-db.org/). The mass
spectrometry data have been deposited to the ProteomeX-
c h a n g e Con s o r t i um ( h t t p : / / p r o t e ome c e n t r a l .
proteomexchange.org) via the PRIDE partner repository with
the data set identiﬁer PXD001038.23
■ RESULTS
Initial Molecular Characterization of OCT Embedded and
Nonembedded Human GBM Tumors
For all analyses, tumor tissue specimens were available from
eight patients. Seven of the patients had paired tumor tissue
samples, in which one piece of the tumor had been OCT-
embedded prior to ﬂash freezing, whereas the other piece of the
tumor had been immediately ﬂash-frozen upon resection. For
the eighth patient, only two independent immediate ﬂash
freezing (iFF) tumor pieces were available (Table 1). These
samples were included to assess the physiological variation and
potential eﬀects of diﬀerent preservation and storage methods
relative to variation of the analytical process. Initial molecular
characteristics of each of the eight patient tumors was carried
out using immunoblotting to identify the expression status of
EGFR, Her3, PDGFRα, PDGFRβ, Met, Akt pS473, and p53
(Figure 1B). A diverse array of expression levels of these RTKs
was detected, with EGFR, Her3, Met, PDGFRα, and PDGFRβ
each variably expressed in this panel. To identify the eﬀect of
altered expression of these RTKs on signaling in these tumors
we also carried out immunoblotting of total phosphotyrosine
(Figure 1B). Distinct signaling proﬁles for each of the eight
patient tumors can be seen in this blot, emphasizing the need
for quantitative analysis of tyrosine phosphorylation signaling
networks with site-speciﬁc resolution. Overall, from these blots
it was clear that the expression and signaling levels were similar
for the OCT compound embedded and the iFF tumor sections
(Figure 1B).
Quantiﬁcation of Protein Expression Proﬁles and
Phosphotyrosine Signaling Across OCT Embedded and
Nonembedded Human GBM Tumor Sections
One of the primary concerns in analyzing signaling networks in
tumor tissue specimens is that the phosphorylation status may
no longer be representative of the physiological state due to
alterations associated with the preservation and storage method
of the tissue. To assess potential diﬀerences arising from OCT-
embedding vs immediate ﬂash-freezing of the tumor, we used
mass spectrometry, combined with 8-plex iTRAQ isotopic
labeling, to perform in-depth quantiﬁcation of the phosphotyr-
osine signaling and protein expression proﬁles across the paired
sets of GBM tumor tissue specimens from seven patients, along
with replicate samples of the iFF tissue from the eighth patient
(Figure 1A). Tyrosine phosphorylation-mediated signaling
networks were quantitatively proﬁled using phosphotyrosine
IP followed by liquid chromatography tandem mass spectrom-
etry (LC−MS/MS) as previously described.16 Protein
expression proﬁling was carried out using isoelectric fractiona-
tion followed by LC−MS/MS using a 5600 triple ToF
instrument.16 Phosphotyrosine and protein expression proﬁling
across the 16 GBM tumor sections resulted in the identiﬁcation
and quantiﬁcation of 402 phosphotyrosine peptides and 1877
protein groups. The overlap of the identiﬁed and quantiﬁed
phosphotyrosine peptides and proteins are depicted in Venn
diagrams (see Supporting Information Figure S2A, B, and C
and Supporting Information Figure S2D, E, and F respectively).
Correlation Analysis of Phosphotyrosine Signaling Across
Diﬀerentially Processed GBM Tumor Sections
To assess the similarity of the diﬀerent tumor sections based on
their phosphotyrosine proﬁles, unsupervised hierarchical
clustering was performed on the log2-transformed iTRAQ
ratios using one minus Pearson’s correlation as a distance
metric. Each of the diﬀerentially processed human GBM tumor
pairs (1, 3, 4, 5, 6, 7, and 8) and the two iFF sections of tumor
2 (2Fa and 2Fb) clustered together (Figure 2A), indicating a
high degree of similarity between separate pieces of the same
tumor. To generate a more quantitative view of the comparison
between OCT and iFF tissue samples from the same patient
compared to samples from other patients, we carried out a
correlation analysis of the 16 GBM tumor sections based on the
107 phosphotyrosine peptides overlapping in 14 or more of the
tumor sections. The correlation matrix for this analysis is shown
in Figure 2B. Each of the seven diﬀerentially processed tumor
pairs can be shown to correlate with an average R2 value of
0.737 ± 0.155. The two iFF sections of tumor 2 correlated with
a similar R2 value of 0.792 while the average correlation
coeﬃcient for all pairwise analyses was found to be a
signiﬁcantly lower, with an average R2 value of 0.090 ±
0.181. These results indicate that diﬀerences resulting from
postexcision processing and storage are minimal, especially in
the context of the interpatient heterogeneity. These analyses
(1) underscore that diﬀerent pieces of the same tumor are
highly similar and thus the signaling networks identiﬁed in each
piece may be representative of the signaling in the tumor as a
whole and (2) provide further proof that tyrosine phosphor-
ylation signaling networks found in each patient’s tumor are
distinct, even when those tumors may express similar activated
RTKs.
To gain additional insight into the potential diﬀerential
eﬀects of OCT-embedding compared to immediate ﬂash-
freezing, we directly compared the mass spectrometry signal
intensity for each phosphopeptide in each matched pair of
tumor samples by plotting the log2 iTRAQ intensity for the
OCT section of the tumor vs the iFF section of the tumor
derived from the same patient and carried out simple linear
regression (Figure 2C). The average R2 value for the correlation
of each matched pair of tumor samples was 0.878 ± 0.046 for
the seven tumor pairs, whereas the two iFF sections of tumor 2
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Figure 3. Protein expression proﬁling highlights signiﬁcantly diﬀerent expression patterns across GBM patients but a high degree of similarity
between OCT and ﬂash frozen processed tumors. (A) The 1037 overlapping protein groups quantiﬁed across all 16 OCT compound embedded and
ﬂash frozen GBM tumor sections are visualized in the heat map. iTRAQ ratios were normalized to tumor section 5F, normalized to the mean and
log2 transformed. Tumor sections and protein groups were hierarchically clustered using one minus Pearson’s correlation distance metric. (B) A
correlation matrix of all 16 tumors sections based on the quantitative protein expression data. The Pearson’s coeﬃcients between every pair of tumor
sections are displayed in each box. The color bar indicates the correlation coeﬃcients, where red indicates positive correlation and blue indicates
negative correlation. (C) A pie chart diagram displaying the PANTHER GO biological processes annotation analyses carried out for the 1037
overlapping protein groups. (D) A pie chart diagram displaying the PANTHER GO protein classes’ annotation analyses carried out for the 1037
overlapping protein groups.
Journal of Proteome Research Article
dx.doi.org/10.1021/pr500418w | J. Proteome Res. 2014, 13, 4581−45934586
correlated with an indiscriminate R2 value of 0.823. By
comparison, the average R2 correlation for the OCT and iFF
sections from non-matched patients was 0.599 ± 0.074
(Supporting Information Figure S3). These correlation values
for matched pairs were found to be signiﬁcantly greater (p =
9.878 × 10−5) than correlation values for non-matched pairs, as
determined by a paired TTEST.
Correlation Analysis of Protein Expression Proﬁles Across
Diﬀerentially Processed GBM Tumor Sections
Protein expression analysis resulted in the identiﬁcation and
quantiﬁcation of 1877 protein groups across human GBM
tumors, with 1037 protein groups quantiﬁed across all 16 tumor
sections. To identify the similarity of the diﬀerent tumor
sections based on their protein expression proﬁles we carried
out hierarchical clustering on these overlapping proteins. As
with the phosphotyrosine data, all eight pairs of GBM tumors
clustered together in this analysis (Figure 3A). Correlation
analysis of the 16 tumor sections based on the 1037
overlapping proteins (Figure 3B) further emphasized the
similarity between 2 separate pieces of the same tumor. The
seven tumor pairs that were diﬀerentially processed correlate
with an average R2 value of 0.767 ± 0.089, while the two iFF
sections of tumor 2 correlate with a similar R2 value of 0.735. In
contrast, the average correlation coeﬃcient for all pairwise
analyses was found to be a signiﬁcantly lower, with an R2 value
of −0.046 ± 0.258. These results stress the signiﬁcant
diﬀerences in protein expression proﬁles between each of the
eight tumor samples, indicating a large degree of interpatient
heterogeneity at the signaling level and at the protein
expression level. This analysis indicates that the intertumor
heterogeneity is signiﬁcantly greater than the combination of
intratumor heterogeneity and any alterations introduced
through the OCT embedding procedure.
To identify coverage of the protein expression analysis we
carried out GO annotation analysis. The protein classes and the
biological functions of the 1037 overlapping proteins are
displayed in pie charts in Figure 3C and D respectively. We
attempted to identify proteins that were diﬀerentially aﬀected
by the OCT vs iFF preservation techniques within each of
these classes and biological functions; however, we were unable
to identify changes that were statistically signiﬁcant across
multiple tumors. Although we could not identify any
statistically signiﬁcant changes with OCT embedding, we did
identify subtle but signiﬁcant changes in a group of
phosphorylation sites that were quantiﬁed across all experi-
ments (Supporting Information Figure S4). These subtle
changes are likely indicative of either intratumor heterogeneity
or patient-speciﬁc eﬀects of OCT-embedding. In either case,
the variance in paired pieces from a given tumor was muted
when compared to intertumor heterogeneity.
Deﬁning Pathways by Coclustering of Quantitatively
Similar Phosphorylation Sites
Because the tyrosine phosphorylation data was highly similar
between two sections of a given tumor, we reasoned that this
phosphorylation data might be an accurate representation of
the signaling networks in the overall tumor. Extracting activated
signaling networks from relative quantiﬁcation data for
hundreds of phosphorylation sites can be challenging, especially
given the high interpatient heterogeneity and the limited
number of samples. Here, to highlight the phosphorylation sites
that were most commonly coregulated and may therefore
deﬁne networks, we combined hierarchical clustering and
correlation analysis of the 107 tyrosine phosphorylation sites
quantiﬁed in all 16 tumor tissue specimens. The correlation
matrix resulting from this approach (Figure 4A) revealed ﬁve
distinct clusters containing ﬁve or more phosphorylation sites.
Figure 4. Correlation analyses across the 107 overlapping phosphotyrosine sites reveal clusters of phosphorylation sites with similar quantitative
proﬁles across the 16 tumor sections. (A) Phosphotyrosine peptides were hierarchically clustered using one minus Pearson’s correlation distance
metric prior to correlation analysis. The cluster numbers are indicated on the top and right-hand side of the correlation matrix. (B) Zoomed in
correlation matrix showing cluster 3 and 4, which includes 56 phosphotyrosine sites. Protein and phosphotyrosine site is labeled at the top and right-
hand side of the correlation matrix. The color bars in (A) and (B) indicate the correlation coeﬃcients, where red indicates positive correlation and
blue indicates negative correlation. The 18 phosphotyrosine sites that are overlapping cluster 3 and 4 are highlighted by a dashed line.
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Correlation coeﬃcient values and corresponding p-values for
these ﬁve clusters can be found in Supporting Information
Table S3. Clusters 3 and 4, the two largest clusters, were
composed of 56 tyrosine phosphorylation sites; these clusters
are depicted in Figure 4B. Although these clusters of sites
represent highly correlated phosphorylation sites, coregulation
does not necessarily deﬁne a network. To extract networks
from these coregulated clusters, we queried the STRING
database to identify known and predicted protein−protein
interactions (see Supporting Information Figure S5A and B).
Activated Signaling Networks Deﬁned by Quantitative
Tyrosine Phosphorylation Data
Clusters 3 and 4 were both found to be highly interactive.
Cluster 3 includes many proteins and phosphorylation sites
associated with the Integrin-Src-FAK signaling pathway which
regulates focal adhesions, migration, and cell invasion, and is
most strongly phosphorylated in GBM tumor sections 8O, 8F,
1O, and 1F (see cluster 3, Figure 2A). Many of the
phosphotyrosine sites in this cluster are ≥2 fold higher in
tumors 1 and 8 relative to the remaining tumors; this change is
statistically signiﬁcant relative to the average coeﬃcient of
variation (CV) across the technical replicate analyses (15.69 ±
4.090%). Furthermore, the average CV for biological replication
between the two diﬀerentially processed tumor sections (23.37
± 7.870%) was found to be slightly, but signiﬁcantly, greater
than the technical variation (p = 0.03). Phosphorylation sites
on proteins in this cluster known to be involved in focal
adhesions and the integrin-Src-FAK pathway include the Src
family kinases (SFK) Src/Fyn/Yes (pY420), p130Cas (pY249;
also known as BCAR1), SHP-2 (pY62), Paxillin (pY118), N-
WASP (pY256), ITGB4 (pY1207), SHP-2 (pY62), SHPS1
(pY496), and PIK3R1 (pY580). This pathway leads to
cytoskeletal remodeling; accordingly, multiple phosphorylation
sites on proteins associated with this process were also
contained in this cluster: ABI1 (pY213), SPTAN1 (pY1261;
also known as spectrin), tensin2 (pY483), and talin 2
Figure 5. Phosphotyrosine sites that cluster together are functionally related. Log2 transformed iTRAQ ratios for all 16 tumor sections are plotted in
the graphs, and the associated phosphotyrosine site is labeled on the y and x axis. R2 values associated with pairwise correlation analyses are displayed
in the top left-hand corner of each graph. (A) Graphs showing correlations between EGFR autophosphorylation sites. (B) Graphs showing the
correlations between phosphorylation sites involved in actin binding and cytoskeleton. (C) Correlation between SHP-2 and the associated SHP-2
docking protein SHPS1. (D) Graphs showing the correlations between RTK internalization phosphorylation sites on Erbin and Hrs are plotted.
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(pY1665). Many of the sites on these proteins have been
implicated as SFK substrates.
Cluster 4 also features protein phosphorylation sites that
have been linked to cell migration and SFK activity.
Intriguingly, several sites in this cluster are associated with
negative regulatory signaling, including multiple sites (pY227,
pY417, and pY341) on phosphoprotein associated with
glycosphingolipid microdomains 1 (PAG1), a Src-family kinase
substrate whose phosphorylation negatively regulates SFK
activity. These sites correlate strongly with the Hck pY411/
Lyn pY397 activating tyrosine phosphorylation sites. Cluster 4
also includes sites on Erbin and Hrs, proteins involved in the
endocytosis and traﬃcking of activated RTKs. EGFR 1086,
PI3K, and PLC-gamma phosphorylation sites are also included
in this cluster; these sites have recently been shown to function
coordinately in the macrophage-induced migration and
invasion of gastric cancer cells. Sites in cluster 4 were found
to be increased in tumor sections 6O, 6F, 1O, and 1F (see
cluster 4, Figure 2A). Eighteen phosphorylation sites in cluster
4 signiﬁcantly correlated with cluster 3 (Figure 4B), potentially
due to the association of both clusters with cell migration and
SFK activity.
Figure 6. Hierarchical clustering and correlation analysis of protein expression proﬁles across 1037 protein groups quantiﬁed across 16 human GBM
sections reveals groups of functionally related proteins. (A) Correlation matrix of 1037 protein groups based on their quantitative proﬁles. The
protein groups were hierarchically clustered prior to the calculation of Pearson’s correlation coeﬃcients. The cluster numbers are indicated on the
top and right-hand side of the correlation matrix. (B) Zoomed in correlation matrix showing cluster 7, which includes 63 proteins. Protein names are
labeled at the top and right-hand side of the correlation matrix. The color bars in (A) and (B) indicate the correlation coeﬃcients, where red
indicates positive correlation and blue indicates negative correlation. The color bars indicate the correlation coeﬃcient, where red indicates positive
correlation and blue indicates negative correlation.
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Correlating Signaling Nodes
To emphasize signaling nodes that were signiﬁcantly correlated
we selected phosphorylation sites involved in EGFR signaling,
actin binding and cytoskeleton, SHP-2 and SHPS1 interactions,
RTK internalization and cell adhesion (Figure 5 A−D). Among
the EGFR autophosphorylation sites, it is intriguing that EGFR
pY1173 is correlated with pY974 (R2 = 0.851) and with pY1086
(R2 = 0.768) but not with EGFR pY1148 (R2 = 0.158). In
agreement with a recently published study, EGFR site Y1086 is
correlated with PLCG1 pY1253 (R2 = 0.867), although the
SH2 domain of PLC-gamma has not been shown to interact
with EGFR Y1086 in vitro (Figure 5A). Tyrosine phosphor-
ylation of multiple actin binding and cytoskeletal proteins were
found to be highly correlated throughout these analyses, as
shown by the strong correlation between tensin 1 pY366 and
vimentin pY61 (R2 = 0.8035), tensin 1 pY366 and girdin
pY1799 (R2 = 0.858), tensin 1 pY366 and nestin pY928 (R2 =
0.922), and nestin pY928 and vigilin (R2 = 0.8369) (Figure 5B).
SHPS1 is a docking protein which induces the translocation of
SHP-2 from the cytosol to the plasma membrane, whereas
SHPS1 pY496 positively correlates with SHP-2 pY584 (R2 =
0.5332), SHPS1 pY496 does not correlate with SHP-2 pY62
(R2 = 0.157) (Figure 5C), potentially indicating diﬀerential
kinase or phosphatase regulation of these sites. Tyrosine
phosphorylation sites involved in EGFR internalization are
coregulated, with Erbin pY1104 positively correlated with Hrs
pY216 R2 = 0.687 (Figure 5D).
Identiﬁcation of Functionally Related Groups of Proteins in
GBM
Although activated signaling networks are critical for driving
cellular transformation, altered protein expression can also be
critically important in regulating cell biology, and may expose
additional potential therapeutic intervention points. To identify
groups of proteins that are coexpressed, we performed
hierarchical clustering followed by correlation analysis to
generate a correlation matrix (Figure 6A) of the 1037
overlapping protein expression proﬁles across 16 GBM tumor
specimens. To identify the level of intertumor variation at the
protein level, we calculated the average CV across technical
replicate analyses (8.900 ± 1.510%) and the CV for biological
replicate analyses (11.00 ± 2.483%). Through TTEST analysis,
the biological variation was found to be greater than the
technical variation between replicate analyses of the same
sample (p = 0.05). Correlation coeﬃcient values and
corresponding p-values from this analysis are available in
Supporting Information Table S4. From these 1037 proteins,
we identiﬁed eight statistically signiﬁcant clusters containing 10
or more proteins. To identify previously characterized protein−
protein interactions within these clusters we queried the
STRING database. Clusters 7 and 8 iterate coregulation of
proteins involved in transcription, translation, and protein
degradation (Supporting Information Figure 6A and B). For
transcription-associated proteins, cluster 7 consists of many
members of the heterogeneous ribonucleic complex including
HNRNPH1, HNRNPL, HNRNPU, HNRNPR, HNRNPK,
HNRNPM, PTBP1, and FUS (Figure 6B), along with the RNA
binding proteins RBM8A, THOC4, and RALY. Cluster 8
contains the eukaryotic translation initiation factors EIF4B and
EIF4H, both of which are involved in binding mRNA to
ribosomes. Translation associated proteins in these clusters
include multiple ribosomal proteins: RPL3, RPL4, RPL8,
RPL10, RPL13, RPL15, and RPL28 are all present in cluster
7 along with degradation associated proteins PSMC3 and
PSMA6 from the 26S proteasome.
■ DISCUSSION
Despite the prevalence of genetic alterations in RTKs in GBM
tumors, therapeutic agents targeting these putative oncogenic
kinases have fared poorly in the clinic. Identiﬁcation of
activated signaling networks downstream of altered kinases
may provide novel therapeutic targets while giving insight into
the pathways and networks regulating oncogenesis and
progression. To assess activated signaling networks, we proﬁled
phosphotyrosine signaling and protein expression in GBM
tumors from eight patients, including 16 total tumor specimens:
7 pairs of diﬀerentially processed human GBM tumors, and 1
pair of similarly processed tumors (Figure 1). Quantiﬁcation of
proﬁles across OCT compound embedded and nonembedded
ﬂash frozen tissues led to the identiﬁcation of 402
phosphotyrosine sites and 1037 protein groups across 16
human GBM sections. Hierarchical clustering and correlation
analysis of the 16 tumors sections based on the phosphotyr-
osine and protein expression proﬁles led to the observation that
diﬀerentially processed tumor sections clustered together and
were signiﬁcantly correlated at both the protein and
phosphotyrosine level. This high degree of similarity indicates
that the OCT-embedding procedure does not signiﬁcantly alter
the signaling networks or the protein expression proﬁles
relative to immediate ﬂash-freezing of the resected tumor
sample. In fact, more in-depth analysis of the phosphorylation
and expression data failed to reveal any consistent, statistically
signiﬁcant changes between the OCT-embedded and the iFF
samples. Based on these results, we were conﬁdent in using
both OCT-embedded and iFF samples for the quantitative
analysis of activated signaling networks in vivo (Figure 2 and
3). Quantitative signaling and expression proﬁling revealed a
large amount of interpatient heterogeneity across the 8 GBM
tumors at both the phosphotyrosine and protein expression
level. Intriguingly, intratumoral heterogeneity, identiﬁed across
many diﬀerent cancer types, was not observed within these
analyses, as indicated by the high degree of similarity in the
protein expression and phosphotyrosine data between two
separate specimens of the same tumor sample. We expect that
this lack of intratumoral heterogeneity may be due to
population averaging across a large number of cells, as each
tumor tissue specimen consisted of >107 cells.24,25 Further-
more, the time associated with OCT embedding in this study
was minimal; we expect that this has signiﬁcantly contributed to
the maintenance of phosphorylation events in these tissue
specimens. We envisage that longer delays between resection
and freezing (ischemia time) have the potential to signiﬁcantly
alter the phosphorylation status of signaling networks within
the tumor specimens. Thus, when identifying sample
preservation methods it is essential to consider the time
required, as the ischemia eﬀects may deleteriously aﬀect
interpretation of the signaling networks.
Hierarchical clustering and correlation analysis of the
quantitative phosphotyrosine proﬁles uncovered potential
network associations that may be important for inducing
growth and invasion in these tumors samples. Speciﬁcally, the
Integrin-Src-FAK signaling pathway was found to have
increased phosphorylation in GBM tumors 1 and 8 relative
to the other tumor samples (Supporting Information Figure
5A). Because increased phosphorylation of many of the
components of the pathway have been associated with
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increased pathway activation, it is likely that this promigratory
pathway is strongly activated in these two tumors.
Phosphorylation of the focal adhesion proteins,PXN
(pY118), spectrin 1 (pY1261), talin2 (pY1665), and tensin2
(pY468), are present within cluster 3 and are known to be
phosphorylated by Src family kinases.26 Integrin B4 (ITGB4)
has also been shown to activate Src signaling and propagate
signaling through the Ras-extracellular signal-regulated kinase
(ERK) cascade to promote anchorage-independent growth and
invasion downstream of Met activation.27,28 These results
highlight the activation of the Integrin-Src-FAK pathway in
driving migration and invasion in selected GBM tumors. The
increased phosphorylation levels on this pathway in GBM
tumors 1 and 8 indicate a potential therapeutic role for
dasatinib, an SFK-family inhibitor, in these selected tumors.
Further analysis uncovered the identiﬁcation of phosphor-
ylation events involved in the negative regulation of EGFR/
RTK signaling (Supporting Information Figure 5B). Erbin has
been shown to inhibit ERK activation by disrupting Raf-1
binding and subsequent activation by active Ras.29 Phosphor-
ylation of CRIP2 was also associated with this group of
phosphorylation sites. CRIP2 was identiﬁed as a tumor
suppression gene in nasopharyngeal carcinoma (NPC) and
has been shown to act as a transcription repressor for NF-κB,
inhibiting tumor growth and angiogenesis.30,31 In addition, this
cluster also includes activating Hck/Lyn tyrosine phosphor-
ylation sites which correlated with PAG1 tyrosine phosphor-
ylation. The interaction between Lyn and PAG has previously
been identiﬁed to initiate activation of PI3K cascade of
signaling events that may play a role in GBM pathogenesis.32
The C-terminal Src kinase binding protein, PAG1 (Cbp), has
also been shown to mediate negative feedback to Src family
kinases.33 Together, these results assert the importance of
transcription regulation, adaptor and scaﬀolding proteins in the
regulation of RTK signaling in GBM.
Interrogation of individual phosphorylation site correlations
revealed the signiﬁcant correlation of SHPS1 (SIRPa) Y496, a
docking protein responsible for inducing the translocation of
SHP-2 from the cytosol to the plasma membrane, with SHP-2
pY584. The tyrosine phosphorylation of SHPS-1 at both pY449
and pY473 is required for the association of SHPS-1 with SHP-
2 that negatively regulates RTK induced cell adhesion.34
Phosphorylation of SHPS1 Y496 was positively correlated to
SHP-2 pY584 but not to SHP-2 pY62. This level of detail
highlights the site-speciﬁc regulation of phosphorylation and
indicates potential site-speciﬁc interactions that are detectable
through correlation analysis of quantitative tyrosine phosphor-
ylation data, as we have shown previously in cell lines.
Protein expression proﬁling indicated that the eight tumors
within this analysis were signiﬁcantly diﬀerent at both the
phosphotyrosine and protein expression levels, aﬃrming
complex interpatient heterogeneity. Correlation analysis of
the quantitative protein expression proﬁles identiﬁed function-
ally related groups of proteins that are signiﬁcantly diﬀerently
expressed across the eight GBM tumors. Speciﬁcally, transcrip-
tional regulators and heterogeneous ribonucleic complex
proteins were diﬀerentially expressed, as were multiple splicing
factors. Several of these proteins have been previously
implicated in tumorigenesis and tumor progression. For
instance, the splicing factor PTBP1 (Figure 6B) has previously
been identiﬁed to play a role in the inﬁltrative nature of cell in
GBM, with PTBP1 involved in cellular proliferation, cell
motility and focal adhesion complexes.35 The translation
initiator EIF4H1 has been implicated in tumorigenesis;36
deciphering the role of this protein in developed GBM tumors
may reveal additional insights about its regulation. Reduced
expression of hnRNPH plays a direct role in enhancing tumor
aggressiveness by inhibiting apoptosis and promoting invasion
in GBM.37 These results highlight multiple potential points of
dysregulation in signaling networks, RNA transcriptional
processing, and protein translation. Integration of these data
sets may reveal novel connections between altered signaling
and the detected alterations in protein expression. Whether
these results implicate novel points of therapeutic intervention
remains to be determined, but through quantitative mass
spectrometric analysis of protein expression and phosphor-
ylation, it is possible to detect activated networks in speciﬁc
tumors. The large amount of interpatient heterogeneity
detected here accentuates the complexity of this disease and
the diﬃculty in successfully treating patients.
Results generated in this study highlight the application of
quantitative signaling analyses for the identiﬁcation of activated
networks in clinical samples. Moreover, they demonstrate that
OCT-embedded samples preserve the integrity of physiological
protein expression and protein phosphorylation signaling
networks. Finally, clustering and co-occurrence analysis enables
the identiﬁcation of activated signaling networks from complex,
heterogeneous data.
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Curated annotated mass spectra of the 402 quantiﬁed
phosphotyrosine sites can be found in ﬁgure S1. The
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